Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail

Skye Bioscience’s nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when combined with Wegovy, according to analysts at William Blair.